Tags : Purchases

Daiichi Sankyo Acquires Rights for Astellas’ Three Therapies to Boost

Shots: Astellas to receive ~$88.3M as up front for its three products. Daiichi to get rights and obligations, including manufacturing and marketing approvals for Nasea (ramosetron), Perdipine (nicardipine) and Oldeca (barnidipine) from Dec’2019 The focus of the agreement is to strengthen Daiichi’s presence in Asia and to contribute to healthcare in Asia by acquiring two […]Read More